SEC Form 4 · accession 0001572426-16-000224
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jurgen Horn
Officer — Chief Product Development Ofcr
Period of report
Sep 5, 2016
Accepted (ET)
Sep 7, 2016 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | Sep 5, 2016 | M | 63,000 | A | — | Jul 1, 2021 | Ordinary Shares | 63,000 | 63,000 | D |
Explanation of responses
- F115,750 of the Restricted Share Units shall vest and become convertible on each of 7/1/17, 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.